Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kinex names Michael Murphy director

This article was originally published in Scrip

Executive Summary

Buffalo, New York-based Kinex Pharmaceuticals has named Michael Murphy to its board of directors. In parallel, Dr Jean-Pierre Sommadossi is stepping down from the company's board, but will continue to act as a senior advisor to Kinex's CEO Dr Johnson Lau. Mr Murphy is a senior partner at law firm DLA Piper. He is also a founding member of the private equity and angel investment firm Shadow Rock with holdings in the pharmaceutical, technology, real estate and other sectors. He said as an investor with Kinex he has been "consistently impressed" by the firm which he says has a "strong and impressive pipeline of clinical oncology drug candidates." Mr Murphy is based out of DLA Piper's New York, London and Hong Kong offices.

You may also be interested in...

Building The Talent Pipeline Starts With Access For All

Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives. 

Snapshot: October Highlights

A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.

Execs On The Move, Oct 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts